GSK and Moderna settled all pending patent infringement lawsuits in the U.S. and Europe. The disputes centered on mRNA technology used in Moderna's vaccines. GSK claimed Moderna’s COVID-19 vaccines, Spikevax and mNEXSPIKE, infringed its patents. GSK also claimed Moderna’s RSV vaccine, mResvia, infringed its patents. These patents covered lipid nanoparticle technology, which delivers mRNA into the body.
As part of the resolution, the companies entered a mutual cross-licensing agreement for infectious disease patents. The settlement requires no payments from either party. Both companies requested the dismissal of the U.S. federal court case with prejudice, meaning the claims cannot be refiled. This agreement provides legal clarity for both drugmakers.